Financial news
Written by: Jingjing He
2020-02-20 09:47
Last updated: 2020-02-20 09:48Yongsheng Medical (1612) announced that the respiratory humidification device has been issued a medical device registration certificate issued by the China Food and Drug Administration. The device is a non-invasive high-flow oxygen treatment device for chronic or acute respiratory distress, such as pneumonia, Patients with viral pneumonia, chronic obstructive pulmonary disease, heart failure and asthma have been accredited by the Japanese Ministry of Health, Labour and Welfare and Conformité Européenne ("CE") in 2018 and 2019.
Yongsheng refers to the fact that it has received preliminary orders from Hubei Province for the O2FLO respiratory humidification therapy instrument and related disposable products. It is believed that the device has good market potential and will be committed to registering and launching the device in the United States and other countries.
Stimulated by the news, Yongsheng's stock price opened 25% higher this morning, reported at 0.75 yuan, the latest reported 0.73 yuan, up 21%, temporarily recorded 4.16 million yuan in transactions.
Transaction stock